Statistics

Total Visits

Views
Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 1)14

Select a period of time:

Number of views in the range

Views
Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 1)6

Views

Views
November 20230
December 20230
January 20242
February 20240
March 20241
April 20241
May 20242
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States6
 

Top cities views

Views
Boardman1